Dupixent Approved for Bullous Pemphigoid

A Message from our Executive Director

Dear IPPF Community,

Today, I’m incredibly grateful to share the exciting news that the U.S. FDA has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP)!

As you may know, the IPPF has worked closely with our industry partners at Sanofi and Regeneron, government regulators, medical professionals, and advocates, all in hopes of seeing this day arrive. While these collaborations have been critical, the most important efforts along this journey have come from you: the patients and caregivers who have shown tremendous courage and strength during some of the most difficult days of your lives.

If you have ever participated in a clinical trial, spoken up at an IPPF event, hosted or attended a support group, shared your story, connected with another patient, spent a few minutes educating someone about your disease, made a donation, or simply been present with us, this is your win. Even if you don’t have BP, by being a part of the IPPF community, you helped make this landmark approval happen.

In the coming days, many of you will have questions about what this approval means for individual BP patients. The IPPF is actively working to find the right resources to answer your questions and to learn what comes next for patients hoping to access Dupixent.

Please note that although Dupixent has been approved, it typically takes some time for payors (i.g., insurance companies) to add new approvals for coverage. As always, the best resource for your individual situation is your treating medical team. The IPPF staff are not doctors, so we cannot make recommendations on how to treat your specific case. However, we are here to be a clearinghouse of information about your disease, and we will share more details about Dupixent very soon.

To learn more about Dupixent and its approval for BP, I encourage you to read this morning’s press releases from Sanofi and Regeneron:

Sanofi press release
Regeneron press release

Thank you for being an essential part of the IPPF community. Without YOU, none of this would be possible!

Sincerely,

Patrick Dunn
IPPF Executive Director